Purpose: To describe a case of fulminant bilateral papillitis and chorioretinitis in the setting of positive coxsackievirus B titers, which convalesced months after the patient's presentation. The patient presented with an acute posterior multifocal placoid pigment epitheliopathy-like clinical picture and her visual acuity and visual field improved moderately after initiation of treatment with intravenous immunoglobulin.

Methods: Case report of a white female with bilateral blurred vision is presented in this study.

Results: A previously healthy 59-year-old white woman presented with a 3-day history of bilateral blurred vision. Initial visual acuity was hand motion in the right eye and count fingers in the left eye. Extensive workup and imaging was done and she was empirically started on intravenous antibiotics followed 24 hours later by intravenous steroids. The patient was found to have high titers of coxsackievirus B and sustained modest visual acuity and perimetry improvement in one eye after intravenous immunoglobulin infusion.

Conclusion: A case of fulminant bilateral chorioretinitis and papillitis that resulted in bilateral vision loss despite high-dose steroids within 24 hours of initial loss in vision is presented in this study. The patient was found to have high titers of coxsackievirus B3, B4,B5 after presentation and her condition improved after treatment with intravenous immunoglobulin, suggesting a plausible immune component.

Download full-text PDF

Source
http://dx.doi.org/10.1097/ICB.0b013e31828993c6DOI Listing

Publication Analysis

Top Keywords

intravenous immunoglobulin
12
visual acuity
12
chorioretinitis papillitis
8
acute posterior
8
posterior multifocal
8
multifocal placoid
8
placoid pigment
8
case fulminant
8
fulminant bilateral
8
treatment intravenous
8

Similar Publications

Background: Patients on a kidney transplant waiting list with antibodies against more than 80% of a panel reactive antibody (PRA) are difficult to transplant, even with national or regional programs. Desensitization treatment with high-dose intravenous immunoglobulin and rituximab could be offered to patients with a long waiting time for a cadaveric donor to improve their odds of finding a kidney.

Methods: This was a retrospective, single-center study including all hyperimmunized patients on the waiting list for a cadaveric kidney donor who received a desensitization treatment between 2010 and 2020.

View Article and Find Full Text PDF

Pemphigus vulgaris is a severe and often therapy-resistant bullous autoimmune disease. Standard therapy with steroids often administered together with another immunosuppressant does not respond in all patients or may not be a good therapeutic option in patients with severe underlying diseases. Intravenous immunoglobulins (IVIgs) represent a treatment alternative, often showing a rapid response which allows one to reduce concomitant immunosuppression.

View Article and Find Full Text PDF

Immune checkpoint inhibitors (ICIs), such as pembrolizumab, have revolutionized cancer treatment by enhancing the immune system's response to malignancies. However, these therapies are associated with immune-related adverse events (irAEs), including neuromuscular complications such as myasthenia gravis, myositis, and myocarditis. We describe two male patients, aged 67 and 68, with small cell and non-small cell lung cancers, who developed progressive neuromuscular symptoms, including ptosis, diplopia, and generalized weakness, after receiving pembrolizumab.

View Article and Find Full Text PDF

Wearable electrodriven switch actively delivers macromolecular drugs to fundus in non-invasive and controllable manners.

Nat Commun

January 2025

Suzhou Key Laboratory of Nanotechnology and Biomedicine, Institute of Functional Nano & Soft Materials & Collaborative Innovation Center of Suzhou Nano Science and Technology (NANO-CIC), Soochow University, Suzhou, China.

Current treatments for fundus disorders, such as intravitreal injections, pose risks, including infection and retinal detachment, and are limited in their ability to deliver macromolecular drugs across the blood‒retinal barrier. Although non-invasive methods are safer, their delivery efficiency remains suboptimal (<5%). We have developed a wearable electrodriven switch (WES) that improves the non-invasive delivery of macromolecules to the fundus.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!